AIkido Pharma (Nasdaq: AIKI) has entered a securities purchase agreement to sell 11,000 shares each of Series O and P redeemable convertible preferred stock at $952.38 per share, totaling approximately $20.9 million in net proceeds. These shares are convertible into common stock at $1.00 per share, contingent on shareholder approval for a reverse stock split. The Series P shares grant significant voting power on this proposal. The offering is facilitated by H.C. Wainwright & Co., with proceeds intended for working capital and corporate purposes.
AIkido Pharma Inc. (NASDAQ: AIKI) announced a share repurchase program, authorizing the buyback of up to $3 million of its common stock, effective immediately. This decision underscores the Company's commitment to shareholder value and reflects a strong balance sheet. CEO Anthony Hayes stated that the program aligns with the Company's growth strategies and anticipates multiple monetization events in 2022 to enhance shareholder value further.
AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Rachel Yehuda's appearance on CBS News discussing a recent FDA-approved trial involving a psychedelic drug aimed at treating PTSD. The segment highlights a former Marine's struggles with PTSD and his newfound hope through this research. AIkido expresses support for Dr. Yehuda's work and emphasizes its commitment to veterans. The company, founded in 1967, is also involved in developing anti-cancer therapeutics and a broad-spectrum antiviral platform targeting multiple viruses.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced plans to expand its patent applications for its pancreatic cancer drug and antiviral treatments into key international markets, including China, India, and all member countries of the European Patent Office. The company's CEO, Anthony Hayes, emphasized the importance of solid patent protection for future market share. This strategic move is a step towards enhancing the company’s footprint in the global healthcare market.
AIkido Pharma (Nasdaq: AIKI) announced a strategic equity interest in ASP Isotopes, focusing on non-nuclear enriched isotopes, on December 6, 2021. The investment aims to solve supply chain issues for Technetium-99m, derived from molybdenum-100. ASP Isotopes is constructing a 20 Kg/year production plant in South Africa, with high demand from customers. By 2028, they project generating over $150 million in EBITDA. AIkido's CEO highlighted the opportunity for potential monetization in early 2022 amidst a $3.8 billion Mo-99 market. The move aligns with AIkido's strategy to enhance shareholder value.
Summary not available.
AIkido Pharma Inc. (Nasdaq: AIKI) reported its Q3 2021 financial highlights, revealing cash and investments over $104 million with low cash burn. A key achievement was a liquidity event in DatChat, yielding over 600% ROI. The company diversified its investment portfolio, including stakes in Tevva Motors, Kerna Health, Slinger Bag, and Kaya Holdings, targeting high-growth sectors. AIkido is actively advancing its drug platform through partnerships with top universities to develop antiviral therapies. Despite a strong balance sheet, the CEO emphasized that the company's valuation does not reflect its asset value.
AIkido Pharma Inc. (AIKI) announced its equity interest in Tevva Motors Ltd, an electric truck manufacturer. Tevva specializes in modular electrification systems for medium-duty vehicles, tapping into a $100 billion global delivery truck market. CEO Anthony Hayes emphasized the growing demand for cost-effective, zero-emission solutions, with Tevva's technology already in use by partners like UPS and Hitachi. AIkido sees potential for shareholder value through Tevva's upcoming public listing. The company continues to focus on drug development while exploring high-growth opportunities.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced a strategic investment in Kerna Health, a tele-health company focused on digital health monitoring. Kerna Health has established a growing backlog of revenue contracts, currently valued at $25 million and potentially reaching $400 million. The company's technology aids in managing chronic illnesses and is backed by the demand for remote patient monitoring services post-COVID. CEO Anthony Hayes expressed optimism regarding Kerna's future and the potential for an IPO. This move aligns with AIkido's growth strategy aimed at enhancing shareholder value.
AIkido Pharma (Nasdaq: AIKI) has provided a shareholder update discussing recent advancements and potential growth catalysts. The company holds 525,000 shares of DatChat (Nasdaq: DATS), which went public and has generated over $3.4 million in additional assets for AIkido. Their strategy focuses on acquiring biotech assets, with Convergent Therapeutics making progress under new leadership. AIkido's pancreatic cancer asset has received a Notice of Allowance from the USPTO. The company emphasizes its strong financial position with over $100 million in the bank and plans to enhance shareholder value.